Pfizer Inc. (PFE) Q2 2026 (USD): Adj. EPS 0.77 (exp. 0.68), Revenue 15bln (exp. 14.40bln). FY adj. EPS view 2.80-3.00 (exp. 2.94), revenue 60.5-62.5bln (exp. 61.8bln)

Pfizer Inc. (PFE) Q2 2026 (USD): Adj. EPS 0.77 (exp. 0.68), Revenue 15bln (exp. 14.40bln). FY adj. EPS view 2.80-3.00 (exp. 2.94), revenue 60.5-62.5bln (exp. 61.8bln)

A beat on both lines with full-year guidance whose midpoint brackets consensus is the classic large-cap pharma print: the initial read is constructive, but the durable move has tended to depend on guidance composition rather than the quarter itself. For this name in particular, precedent sets the questions: how much of the beat is COVID-franchise revenue versus the core portfolio, since one-off antiviral contributions have repeatedly flattered quarters only to fade in subsequent prints, and how much is pipeline or acquired-asset contribution against patent-cliff exposure. A guide that spans the consensus estimate rather than lifting cleanly above it has historically capped the follow-through in the shares, with the call commentary on margins and LOE offsets doing more work than the headline numbers. Worth watching is whether the full-year ranges were raised from prior guidance or merely reaffirmed, and any colour on the obesity and oncology pipeline read-throughs that have driven the peer set. Sequenced as usual: release, then the call, with the stock's holding of the opening move the tell.